NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) will present at the Barclays
Global Healthcare Conference in Miami, Florida on Tuesday, March 11,
2014 at 9:00 a.m. ET. The presentation will be available as a live
webcast with a replay...
By ONeil Trader:
NPS Pharmaceuticals' (NPSP) successful launch of Gattex and plans for international expansion put the company on a path to significant growth.
Natpara is expected to be approved by the end of 2014...
NPS Pharmaceuticals, Inc. (NPSP)
Q4 2013 Earnings Conference Call
February 18, 2014 5:00 PM ET
Susan Mesco – Senior Director, IR and Corporate Communications
Dr. Francois Nader – President and CEO
Eric Pauwels –...
Macquarie upgrades Fluor (NYSE: FLR) from Neutral to Outperform and moves its price target from $70 up to $98.
Goldman Sachs boosts Actavis (NYSE: ACT) from Neutral to Buy, while adjusting its price target from $185 up to $250. Click...
In a report published Wednesday, Jefferies analyst Eun K. Yang downgraded the rating on NPS Pharmaceuticals (NASDAQ: NPSP) from Buy to Hold, but reiterated the $38.00 price target.
In the report, Jefferies noted, “FY14 guidance/4Q13 sales of...
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a global biopharmaceutical
company pioneering and delivering therapies that transform the lives of
patients with rare diseases worldwide, today announced preliminary
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.